Category Filter
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing
- HelpScript Program
- Hemophilia Drugs
- Medical Policies
- Pre-Service Review (Predetermination/Precertification)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Atopic Dermatitis (Elidel [pimecrolimus], Eucrisa, Protopic [tacrolimus]) Step Therapy Program Summary
Policy Number: PH-1028
This program applies to Commercial, SourceRx, Blue Partner, and Health Insurance Marketplace formularies.
POLICY REVIEW CYCLE
Effective Date |
Date of Origin |
1/1/2024 |
|
FDA APPROVED INDICATIONS AND DOSAGE
Agent(s) |
FDA Indication(s) |
Notes |
Ref# |
Elidel® (pimecrolimus)* Cream 1% |
Second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable |
* generic available |
2 |
Eucrisa® (crisaborole) Ointment 2% |
Topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older |
|
3 |
Protopic® (tacrolimus) Ointment 0.03%, 0.1%* |
Second-line therapy for short-term and non-continuous chronic moderate to severe AD in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for AD, or when those treatments are not advisable (0.03% and 0.1% for adults; 0.03% only for children ages 2-15) |
* generic available |
1 |
See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm
CLINICAL RATIONALE
Atopic Dermatitis |
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that follows a relapsing course. AD occurs most frequently in children, but also affects many adults. Topical agents are the mainstay of AD therapy, with topical corticosteroids being the first-line treatment for mild-to-severe dermatitis in all skin regions.(4,8) Continuous application of topical corticosteroids for long periods of time should be avoided to limit the occurrence of negative changes. Cutaneous side effects include purpura, telangiectasia, striae, focal hypertrichosis, and acneiform or rosacea-like eruptions. Of greatest concern is skin atrophy, especially through use of higher-potency agents, use on thinner skin, and older patient age.(4) Topical calcineurin inhibitors (TCI) such as topical pimecrolimus and topical tacrolimus, are approved as second-line agents for the short-term and noncontinuous chronic treatment of AD in non-immunocompromised individuals who have failed to respond adequately to other topical prescription treatments for AD, or when those treatments are not advisable. TCIs do not carry the risk of skin atrophy with little effect on collagen synthesis and skin thickness. Use of TCIs have been studied in long-term studies to 12 months and have shown to reduce the need for topical corticosteroid use. TCIs may be preferable over corticosteroids in certain situations:
Crisaborole 2% ointment is a topical nonsteroidal treatment for mild to moderate AD. It is well tolerated by most patients. It has shown superiority to emollient treatment alone. There is no data on long-term effectiveness because studies lasted for only 28 days. Crisaborole has not been compared directly with other treatments for atopic dermatitis.(6) |
Psoriasis |
The 2023 American Academy of Dermatology (AAD) Guidelines state that although corticosteroids remain the mainstay of topical therapy for psoriasis, the most potent and efficacious of these agents are approved for only short-term treatment (2-4 weeks). Consideration should be given to use of medications that have been developed to either replace potent topical corticosteroids in longer term treatment, or to be used in combination to provide greater efficacy with lesser exposure to steroid containing agents. Pursuit of these goals with agents including vitamin D analogues, topical retinoids, and TCIs has shown benefit.(7) Although tacrolimus and pimecrolimus have not been found beneficial for plaque psoriasis, these agents have shown some benefit for intertriginous and facial psoriasis.(8) A review (2013) on treatment of psoriasis suggests tacrolimus and pimecrolimus generally improve symptoms with less skin atrophy than topical corticosteroids and are considered first-line treatments for facial and flexural psoriasis. Tacrolimus is superior to pimecrolimus in reducing psoriasis symptoms.(7) |
Efficacy |
Protopic/Elidel A meta-analysis (2016; 12 RCTs) compared calcineurin inhibitors (n=3492) vs. corticosteroids (n=3462) in treatment of atopic dermatitis. Calcineurin inhibitors and corticosteroids had similar rates of improvement of dermatitis (81% vs. 71%; p=0.01) and treatment success (72% vs. 68%; p=0.04). Calcineurin inhibitors were associated with higher costs and had more adverse events (74% vs. 64%; p=0.02) including a higher rate of skin burning (30% vs. 9%; p less than 0.00001) and pruritus (12% vs. 8%; p less than 0.00001). There were no differences in atrophy, skin infections, or adverse events that were serious or required discontinuation of therapy.(5) Though comparative data are limited in regard to high (i.e., betamethasone dipropionate 0.05%) and very high (clobetasol 0.05%) potency steroids, they appear to be more effective than pimecrolimus 1% cream. The comparative data with medium potency steroids are less clear. While they do appear to be more effective than pimecrolimus in terms of change in severity and itch reduction, not all studies reached significance. There does not seem to be a difference in infection risk between pimecrolimus and medium potency TCS. Although tacrolimus 0.1% ointment appears to be more effective than pimecrolimus 1% cream, it may be similarly as effective as medium potency TCS.(8) Eucrisa Four randomized trials comparing crisaborole ointment to vehicle in adult AD were included for analysis. Crisaborole ointment use led to a small but significant improvement in dermatitis in all 4 studies. Across 2 identical trials, 1016 AD patients (aged 2-79 years) were randomized to crisaborole 2% ointment twice daily and 506 to vehicle for 28 days.66 On day 29, significantly more crisaborole-treated patients achieved Investigator's Static Global Assessment success (clear or almost clear with 2-grade or greater improvement from baseline): 326 (32.1%) vs 110 (21.7%) (RR: 1.80, 95% CI: 1.48-2.18, P < .0001). Crisaborole has also demonstrated efficacy in the pruritus of AD in 3 studies. In 40 adults with AD, 2 AD lesions of identical severity were randomized to crisaborole 2% ointment or vehicle twice daily or 14 days. The mean change from baseline in lesion itch NRS at day 15 was greater for crisaborole-treated than vehicle-treated lesions (−3.9 vs −2.0, P < .0001). Crisaborole appears to have a favorable safety profile (i.e., small percentage of patients with application burning, stinging, and/or pain) and discontinuation rate comparable to placebo. Current 2023 AAD guidelines strongly recommends its use for mild-to-moderate AD, based on high certainty evidence.(8) |
Safety |
Elidel is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. Elidel also carries the following black box warning:(2)
Eucrisa is contraindicated in individuals with known hypersensitivity to crisaborole or any component of the formulation.(3) Protopic is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment. Protopic also carries the following black box warning:(1)
|
REFERENCES
Number |
Reference |
1 |
Protopic prescribing information. LEO Pharma Inc. April 2019. |
2 |
Elidel prescribing information. Bausch Health US, LLC. September 2020. |
3 |
Eucrisa prescribing information. Pfizer, Inc. March 2020. |
4 |
Eichenfield LF, Tom WL, Berger TG, et. al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. July 2014;71(1) 116-132. https://www.jaad.org/article/S0190-9622(14)01257-2/fulltext |
5 |
Broeders JA, Ali UA, Fischer, G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. Journal of the American Academy of Dermatology. 2016;75(2):410-419.e3. |
6 |
Castelli G and Schaffer M. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis. Am Fam Physician. 2018 Sep 15;98(6):379-380. https://www.aafp.org/afp/2018/0915/p379.html |
7 |
Weigle N, Mc Bane S. Psoriasis. Am Fam Physician. 2013;87(9):626-633. https://www.aafp.org/afp/2013/0501/p626.html |
POLICY AGENT SUMMARY STEP THERAPY
Agent Names |
Strength |
Targeted MSC |
Available MSC |
Final Age Limit |
Preferred Status |
|
|||||
ELIDEL*pimecrolimus cream ; PIMECROLIMUS*pimecrolimus cream |
1 % |
M ; N ; O ; Y |
O ; Y |
|
|
EUCRISA*crisaborole oint |
2 % |
M ; N ; O ; Y |
N |
|
|
NUJO*tacrolimus (topical) soln ; NUJU*tacrolimus cream ; PROTOPIC*tacrolimus oint ; TACROLIMUS*tacrolimus oint |
0.03 % ; 0.1 % |
M ; N ; O ; Y |
N ; O ; Y |
|
|
CLIENT SUMMARY – STEP THERAPY
Target Brand Agent Name(s) |
Target Generic Agent Name(s) |
Strength |
Client Formulary |
Elidel |
pimecrolimus cream |
1 % |
Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; SourceRx |
Eucrisa |
crisaborole oint |
2 % |
Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; SourceRx |
Nujo ; Nuju ; Protopic |
tacrolimus (topical) soln ; tacrolimus cream ; tacrolimus oint |
0.03 % ; 0.1 % |
Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; SourceRx |
STEP THERAPY CLINICAL CRITERIA FOR APPROVAL
Module |
Clinical Criteria for Approval |
|
TARGET AGENTS Elidel (pimecrolimus cream)* Eucrisa (crisaborole ointment) Protopic (tacrolimus ointment)* * generic available, targeted in program
Target Agent(s) will be approved when ONE of the following is met:
Length of approval: 12 months |
This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.
The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.
Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.
Commercial _ PS _ Atopic Dermatitis (Elidel [pimecrolimus], Eucrisa, Protopic [tacrolimus]) _ST _ProgSum_ 1/1/2024